Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
33%(2 trials)

Phase Distribution

Ph phase_2
1
17%
Ph phase_1
2
33%
Ph phase_3
3
50%

Phase Distribution

2

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 21 (16.7%)
Phase 33 (50.0%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_3

Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®

NCT01803555
completedphase_2

Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients

NCT02227394
completedphase_3

Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma

NCT01099722
completedphase_1

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

NCT02189304
completedphase_1

Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers

NCT01668121
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT01803555Phase 3

Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®

Completed
NCT02227394Phase 2

Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients

Completed
NCT01099722Phase 3

Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma

Completed
NCT02189304Phase 1

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

Completed
NCT01668121Phase 1

Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers

Completed
NCT00319306Phase 3

Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy

Completed

All 6 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
6